Jefferies & Company Reiterates HealthSouth Rating And PT

HealthSouth Corporation HLS remains a compelling LT play in a post-acute subsector with stable reimbursement, Jefferies & Company reports. “The company, which is trading at a compelling 8x FY11 EBITDA, is highly transparent and characterized by predictable, resilient volumes and good cash flows that can be used for debt repayment and growth,” Jefferies & Company writes. “Reiterate Buy/$24PT.” HealthSouth closed Friday at $18.95.